Carey J. Oliver and Shirish Shenolikar

Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710

Received 8/14/98 Accepted 8/20/98

TABLE OF CONTENTS

1.Abstract

2.Introduction

2.1. Introduction to protein serine/threonine phosphatases

2.1.1. Protein phosphatase 1
2.1.2. Protein phosphatase 2A
2.1.3. Protein phosphatase 2B
2.1.4. Other protein serine/threonine phosphatases

3.Protein phosphatase inhibitors

3.1. PP1 inhibitors

3.1.1. Inhibitor-1

3.1.1.1. I-1 and Glycogen Metabolism
3.1.1.2. I-1 and Synaptic Plasticity
3.1.1.3. I-1 and Cell Growth
3.1.1.4. I-1 and Muscle Contraction

3.1.2. DARPP-32

3.1.2.1. DARPP-32 and Na/K-ATPase
3.1.2.2. DARPP-32, Lipogenesis and Lipolysis

3.1.3. Inhibitor-2

3.1.3.1. I-2 and Sperm Motility

3.1.4. NIPP-1

3.1.4.1. NIPP-1 and RNA Metabolism

3.1.5. RIPP-1 3.1.6. CPI17
3.2. PP2A inhibitors

3.2.1. I₁^PP2A
3.2.2. I₂^PP2A

3.3. Endogenous PP2B inhibitors

4. Phosphatase inhibitors and human disease

5.Perspectives

6.References

7. Entire manuscript